Tempsens Instruments IPO GMP Hits 100% Mark; Subscription Surges 22x on Day 2
Source: Economictimes
Arth Insight · What this means for your wallet
- Tempsens Instruments IPO GMP has doubled, indicating a potential 100% listing gain.
- The issue was subscribed 22 times by the end of the second day of bidding.
- This is the first time an IPO has seen a 100% premium in nearly two years.
Wealth-Impact Simulator
See what a one-time investment could grow to.
Indicative estimate for education only — not investment advice.
Explore investmentsTempsens Instruments has become the first IPO in nearly two years to see its Grey Market Premium (GMP) cross the 100% milestone. The issue has seen massive retail and institutional interest, getting subscribed 22 times by the second day of bidding.
- ▸Tempsens Instruments IPO GMP has doubled, indicating a potential 100% listing gain.
- ▸The issue was subscribed 22 times by the end of the second day of bidding.
- ▸This is the first time an IPO has seen a 100% premium in nearly two years.
- ▸The high demand reflects a broader recovery in the Indian IPO market.
- ✓Tempsens Instruments IPO GMP has doubled, indicating a potential 100% listing gain.
- ✓The issue was subscribed 22 times by the end of the second day of bidding.
- ✓This is the first time an IPO has seen a 100% premium in nearly two years.
- ✓The high demand reflects a broader recovery in the Indian IPO market.
Tempsens Instruments is creating a significant stir in the primary market as its Grey Market Premium (GMP) surged past the 100% mark, signaling a potential blockbuster listing for investors. This milestone makes it the first Initial Public Offering (IPO) in nearly 24 months to command such a high premium before its debut on the stock exchanges.
Strong Subscription Numbers
The investor appetite for the Rajasthan-based temperature sensor manufacturer is evident in the subscription data. By the end of the second day of the bidding process, the IPO was subscribed nearly 22 times. This surge is driven by a mix of retail investors and non-institutional bidders looking to capitalize on the positive market sentiment surrounding the manufacturing sector.
Market Context and Sentiment
The performance of Tempsens Instruments is part of a broader revival in the Indian IPO market. Several upcoming public issues are also witnessing strengthening premiums in the grey market, suggesting that the lull in new share sales may be over. Analysts attribute this trend to stable macroeconomic indicators and a renewed interest in mid-cap industrial companies.
What This Means for Retail Investors
A 100% GMP indicates that the shares are trading in the unofficial market at double the issue price. While GMP is not a guaranteed indicator of listing day performance, it serves as a gauge for market demand. Investors should note that high subscription levels often lead to lower allotment chances for individual retail applicants. It is essential to review the company's fundamentals and financial health rather than relying solely on grey market trends.
- Milestone: First IPO to hit 100% GMP in nearly two years.
- Demand: 22x subscription recorded on Day 2.
- Sector: Industrial instrumentation and temperature sensors.
This report is for informational purposes only and does not constitute financial or investment advice.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
IPO investments are subject to market risk and allotment. Read the RHP / prospectus before applying; grey-market premium (GMP) is unofficial and unreliable. Some listings may be sponsored. Not investment advice.
Frequently Asked Questions
What does a 100% GMP mean for the Tempsens Instruments IPO?
A 100% Grey Market Premium (GMP) suggests that the shares are being traded informally at a price double the official IPO price, signaling high investor demand.
How many times was the Tempsens IPO subscribed on Day 2?
The IPO saw a strong response and was subscribed approximately 22 times by the end of the second day.
Is GMP a reliable indicator of listing price?
While GMP reflects current market sentiment and demand, it is an unofficial metric and does not guarantee the actual listing price on the NSE or BSE.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about IPOs
IPOBreakingIndian Primary Market Heats Up: 10 IPOs to Raise Over ₹3,500 Crore This Week
The Indian stock market is set for a busy week with 10 initial public offerings (IPOs) hitting the primary market to raise over ₹3,500 crore. The lineup includes six mainboard issues and four SME offerings, led by the significant Symbiotec Pharmalab IPO.
IPOBreakingSymbiotec Pharmalab Plans ₹150 Crore IPO for Debt Repayment, Expansion
Symbiotec Pharmalab, a global leader in corticosteroid and steroidal-hormone APIs, is planning an Initial Public Offering (IPO) to raise ₹150 crore. The funds are earmarked for repaying existing debt and expanding its operational capabilities. The company has shown consistent revenue and EBITDA growth, primarily driven by its international market presence, particularly in Europe.
IPOBreakingWhy IPO Investing Can Be a High-Stakes Gamble for Indian Retail Investors
While Initial Public Offerings (IPOs) often attract significant interest from Indian retail investors seeking quick gains, a global perspective suggests these investments can increasingly be a high-risk proposition. The allure of new listings must be balanced against the inherent volatility and lack of historical data, making thorough research crucial.
Related Stories
IPOBreakingIndian Primary Market Heats Up: 10 IPOs to Raise Over ₹3,500 Crore This Week
The Indian stock market is set for a busy week with 10 initial public offerings (IPOs) hitting the primary market to raise over ₹3,500 crore. The lineup includes six mainboard issues and four SME offerings, led by the significant Symbiotec Pharmalab IPO.
IPOBreakingSymbiotec Pharmalab Plans ₹150 Crore IPO for Debt Repayment, Expansion
Symbiotec Pharmalab, a global leader in corticosteroid and steroidal-hormone APIs, is planning an Initial Public Offering (IPO) to raise ₹150 crore. The funds are earmarked for repaying existing debt and expanding its operational capabilities. The company has shown consistent revenue and EBITDA growth, primarily driven by its international market presence, particularly in Europe.
IPOBreakingWhy IPO Investing Can Be a High-Stakes Gamble for Indian Retail Investors
While Initial Public Offerings (IPOs) often attract significant interest from Indian retail investors seeking quick gains, a global perspective suggests these investments can increasingly be a high-risk proposition. The allure of new listings must be balanced against the inherent volatility and lack of historical data, making thorough research crucial.
IPOBreakingABH Healthcare SME IPO Opens Monday: Price Band ₹96-102 Per Share
The ABH Healthcare SME IPO is set to open for subscription on Monday. The public issue is a fresh issue of 34.29 lakh equity shares, with a fixed price band of ₹96 to ₹102 per share, aiming to raise capital for the company's growth.